Background
Venous thromboembolism (VTE) is a disease that encompasses all pathological thrombosis occurring on the venous side of the circulation. The most common manifestations are deep venous thrombosis (DVT) of the lower extremities and its potentially fatal complication, pulmonary embolism. VTE accounts for more than 250 000 hospitalizations annually in the USA and causes death in a substantial number of hospitalized patients [1] . Pulmonary embolism has a mortality rate of up to 17% [2] , and approximately 25-30% of patients with proximal DVT will develop symptomatic pulmonary embolism [3] . Among hospitalized patients who experience VTE, up to 5% will suffer a fatal pulmonary embolism [4] . The often clinically elusive nature of this disease is highlighted by one published report in which only 3% of patients who had a DVT present at autopsy had been suspected or evaluated for DVT prior to death [5] . Since sudden death can, in some cases, be the first clinically apparent manifestation of pulmonary embolism, significant attention has been dedicated to the primary prevention of VTE in patients at high risk. In the United States, the Joint Commission and the National Quality Despite the significant risk for VTE among patients hospitalized for 'medical' (i.e. nonsurgical) illnesses, the rate at which prophylaxis measures are used among at-risk subgroups has consistently been reported to be less than 50% [7] . In one study of 2726 patients who were diagnosed with a DVT while in the hospital, only 1147 (42%) had received thromboprophylaxis within 30 days of the diagnosis [3] . Another study demonstrated that only 33% of patients admitted to a medical intensive care unit received VTE prophylaxis, despite the fact that over 50% of these patients had multiple risk factors for VTE [8] . Taking the previous data into account, the low rate of thromboprophylaxis does not correlate with evidence documenting the efficacy of measures designed to reduce VTE risk. Numerous clinical trials have established that the use of pharmacologic or mechanical interventions can substantially reduce the risk of VTE among medical inpatients with risk factors; this evidence has been reviewed elsewhere [9] .
Some authors have speculated that physicians fail to order thromboprophylaxis among medical inpatients because they are unaware of the substantial proportion of patients who are at moderate or high risk of venous thrombosis. Kucher et al. [10] demonstrated that adding electronic alerts for medium-to-high-risk patients within a computerized-physician-order-entry system reduced the number of patients experiencing DVT or pulmonary embolism by 41%. Studies like this suggest that either a knowledge gap or lack of awareness may exist among practitioners. A study evaluating methods to improve VTE prophylaxis by implementing a pharmacy-driven staff education program focusing on the importance of using enoxaparin and heparin in medically ill patients was found to increase the use of appropriate prophylaxis from 43% in the preeducation groups to 58% in the posteducation groups [11] . With these data in mind, we conducted a prospective, controlled study to evaluate the hypothesis that a pharmacist-driven identification and notification system would increase the rate of appropriate thromboprophylaxis use among medical inpatients.
Methods

Patients
All patients admitted to the General Internal Medicine teams at the University of New Mexico Hospital from 19 June 2006 through 21 September 2006 were included. Patients admitted over the weekend were excluded from the study because pharmacist availability on weekends was inconsistent. Patients who were already receiving therapeutic doses of anticoagulants for other reasons were also excluded from the study.
Four internal medicine teams, each composed of a faculty member, house staff and students, admitted all the general medicine inpatients in the same fashion (over a 24-h period) rotating every 4 days. House officers rotated onto a particular team for 1 month at a time. Two of the teams were randomly assigned to be in the intervention group (the other two teams served as the control group) for the duration of the study. A list of all patients admitted to the internal medicine service was provided to the pharmacists every morning, Monday through Friday.
Intervention group
The pharmacist used the history and physical exam available in the hospital chart to determine the patient's VTE risk score. The VTE risk scores were determined by a standardized risk-assessment template ( Fig. 1 ) [10] . Since there is no validated method quantifying the risk of VTE in hospitalized patient, we used a risk assessment model that incorporated risk factors that have, in previously published multivariate analyses, been associated with VTE risk [12, 13] . Patients were risk-stratified and classified as medium or high risk (determined by a score of greater than 4). We arbitrarily chose a score of 4 or above on the risk assessment scale because the level of VTE risk among such patients almost certainly justifies the cost and small risk of hemorrhage associated with prophylactic therapy. Whereas one could make the argument that patients with lower risk scores should also receive prophylaxis, we chose a higher score because we wanted to eliminate any controversy about perceived VTE risk among clinicians as a reason not to administer prophylaxis. Once an at-risk patient was identified, the pharmacist determined if VTE prophylaxis had been ordered. For each such patient, the pharmacist notified the admitting physician on the team about the patient's VTE risk and read a standardized script informing the doctor of the patients' VTE risk, but no specific therapy was recommended. Once a member of the team was contacted by the pharmacist about a given patient, no subsequent attempts were made to contact the team about that patient. The time and date of contact were noted by the pharmacist but no information about the communication was included in the patient's medical record. After being contacted, the physician caring for the patient was then left to decide whether to institute DVT prophylaxis, and if pharmacological prophylaxis was not contraindicated, which evidence-based therapy would be used. If pharmacologic prophylaxis was contraindicated, credit for appropriate prophylaxis was given if sequential compression devices (SCDs) were prescribed.
Control group
For the patients admitted to the two teams designated as the control groups, a record of names and medical record numbers was collected by the pharmacists (using the same method as described above), but no attempt was made to alter the usual care received by these patients.
Outcome measures
At the conclusion of the study, the hospital records of all patients involved in the study were reviewed for time and type of VTE prophylaxis administered. For each patient, the primary outcome measure was whether adequate VTE prophylaxis was ordered within 36 h of admission to the hospital. VTE prophylaxis was considered adequate if one of the following management strategies, available at UNM hospital, was initiated within 36 h of hospital admission: heparin 5000 units subcutaneously every 8-12 h, enoxaparin 40 mg subcutaneously every day, fondaparinux 2.5 mg subcutaneously daily, or SCDs. In addition to the primary outcome, other data were recorded: admitting team, time of admission, age, sex, VTE risk score, contraindications, treatment given, time treatment was ordered and time administered.
Statistical analysis
We estimated that 300 patients would be needed to have power of 90% (two-sided alpha of 5%) to detect an increase in appropriate VTE prophylaxis from 40% in the control group to 60% in the intervention group. Our assumption that 40% of the control patients would receive appropriate VTE prophylaxis was based upon internal data gathered in prior years for quality improvement purposes. Our comparison between intervention and control groups was done by the t-test for continuous outcomes, and by the Fisher's exact test for binary/ categorical variables.
The study was reviewed and approved by the University of New Mexico Health Sciences Center Human Research Review Committee.
Results
Over a 12-week period, 376 patients were admitted to the internal medicine inpatient service between 1900 h Sunday and 0700 h Friday. One hundred and sixty A pharmacy-driven thromboprophylaxis alert system for medical inpatients Garcia et al. 543 patients were admitted to the teams assigned to receive the intervention, whereas 216 patients were admitted to the control teams. This difference in the number of patients admitted to the control versus intervention teams is not attributable to our study methods but rather represents the day-to-day variability in admission volume that can be observed over a short-term period like the one in our study. In the two groups combined, 140 patients met our definition of being moderate to high risk for VTE and were included in the analysis. The characteristics of the included patients are shown in the Table 1 . Overall, 43% of the control group represented women compared to 54% in the interventional group. The average age of patients in the control group was 58, and 61 in the interventional. In the control group, prophylactic measures were ordered for 49 (61%) of the 80 patients at moderate to high risk. In the interventional group, 44 (73%) of the 60 moderate to high VTE-risk patients received adequate thromboprophylaxis. The difference between rates of adequate prophylaxis use in the two groups was not statistically significant (P ¼ 0.15). The most commonly prescribed pharmacologic agents were 'low-dose unfractionated heparin', used in 56% of all atrisk patients, and 'prophylactic dose' enoxaparin, used in 11%. SCDs were used commonly for at-risk patients in both the intervention (64%) and the control (50%) groups; SCDs were commonly ordered along with (rather than in place of) pharmacologic strategies.
Discussion
Our study demonstrates that a pharmacist-driven risk stratification system is associated with a high rate of VTE prophylaxis. Although our study did not find a statistically significant difference between the intervention and control groups, the trend we observed is consistent with the hypothesis that a pharmacist-driven system can increase VTE prophylaxis use among at-risk individuals. It is probable that our study did not achieve statistical significance because VTE prophylaxis use in the control group was substantially higher than we anticipated it would be. On the basis of previous internal surveys, we estimated that 30-40% of the at-risk patients in the control group would receive VTE prophylaxis.
Since the observed rate of adequate VTE prophylaxis in the control group exceeded 60%, our sample size, determined a priori, was not large enough to demonstrate a statistically significant difference. There are several possible reasons the observed rate of adequate VTE prophylaxis within the control group was higher than our prestudy assumptions. First, the internal data on which we based our power calculation were obtained 4 years prior to this study and it is likely that physicians' consciousness of VTE risk among hospitalized patients had increased since that time. Thus, the 'baseline' rate of appropriate VTE prophylaxis at the University of New Mexico Hospital may also have increased. Second, our study design did not prevent or discourage the possibility of cross-talk between the control and interventional groups. It is likely that physicians treating patients in the control group became aware that their practice was being monitored and may have, simply based on this heightened awareness, increased the frequency with which they used thromboprophylaxis [14] . Finally, we overestimated the proportion of patients admitted to the medical service whose VTE-risk score would be 4 or greater. Thus, although we screened 376 patients for inclusion, only 140 were at sufficiently high risk for VTE to include in our comparison.
Computer-based identification of high-risk patients and alerting of physicians in a hospital setting appears to prevent thromboembolic events [10, 15] . Further research is needed to determine whether computer-alert systems, human-alert systems or some combination of the two will be most cost-effective. Although the difference we observed was not statistically significant, our findings suggest that a method relying on person-to-person communication may be an effective alternative, especially in institutions in which computerized order entry is not yet available. In order for a pharmacy-driven identification and notification system to be effective, the pharmacist must have the time and access necessary both to determine each patient's VTE risk as well as to contact the treating physician in a timely manner. Additional studies are needed to establish best practice models for pharmacist-driven thromboprophylaxis. 
